Literature DB >> 30586788

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.

Faiez Zannad1, Patrick Rossignol1.   

Abstract

Entities:  

Keywords:  DPP-4 inhibitors; Editorials; diabetes mellitus; heart failure; trials

Mesh：

Substances：

Year:  2019        PMID： 30586788     DOI： 10.1161/CIRCULATIONAHA.118.038399

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  8 in total

1.  Scientific and ethical issues in add-on designs for antidiabetic drugs.

Authors:  Lidia Staszewsky; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2022-06-22       Impact factor: 3.064

2.  Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.

Authors:  Da-Ya Yang; Xin He; Hui-Wei Liang; Shao-Zhao Zhang; Xiang-Bin Zhong; Chu-Fan Luo; Zhi-Min Du; Jian-Gui He; Xiao-Dong Zhuang; Xin-Xue Liao
Journal:  Cardiovasc Diabetol       Date:  2019-04-08       Impact factor: 9.951

3.  Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.

Authors:  Gian Paolo Fadini; Vera Frison; Natalino Simioni; Annunziata Lapolla; Adriano Gatti; Antonio Carlo Bossi; Andrea Del Buono; Paolo Fornengo; Lucia Gottardo; Mario Laudato; Gianluca Perseghin; Enzo Bonora; Angelo Avogaro
Journal:  J Am Heart Assoc       Date:  2019-07-04       Impact factor: 5.501

4.  GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.

Authors:  Aya Shiraki; Jun-Ichi Oyama; Toshiyuki Nishikido; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2019-11-28       Impact factor: 9.951

Review 5.  Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.

Authors:  Meir Schechter; Matan Fischer; Ofri Mosenzon
Journal:  Diabetes Obes Metab       Date:  2022-03-24       Impact factor: 6.408

Review 6.  DPP4 as a Potential Candidate in Cardiovascular Disease.

Authors:  Si-Yu Chen; Xiang-Quan Kong; Ke-Fan Zhang; Shuai Luo; Feng Wang; Jun-Jie Zhang
Journal:  J Inflamm Res       Date:  2022-09-16

7.  Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.

Authors:  Liyun He; Jialu Wang; Fan Ping; Na Yang; Jingyue Huang; Wei Li; Lingling Xu; Huabing Zhang; Yuxiu Li
Journal:  BMJ       Date:  2022-06-28

8.  Is it Time for Trials on Preventing Immune-Mediated Myocardial Damage?

Authors:  Eliot G Peyster; Kenneth B Margulies
Journal:  JACC Basic Transl Sci       Date:  2021-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.